Answers are grounded in this paper and cite their sources.
Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation. Grade 3 or 4 treatment-related toxic effects occurred in 11.6% of the patients. (Funded by Amgen and others; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).
No takes yet. Share an insight, caveat, or question.
Hong et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: